C. Diehm, 2007 Excess cardiovascular mortality in patients with peripheral arterial disease in primary care: 5-year results of the getABI Study Diehm C,

Slides:



Advertisements
Similar presentations
Summary Prepared by Melvyn Rubenfire, MD
Advertisements

Examination methods in cardiology doc. MUDr. Jaromír Chlumský.
Doc. MUDr. Jaromír Chlumský Leg examination. Ankle Brachial Index ABI: highly specific for leg artery stenosis > 50%, highly sensitive (95 %), takes.
PAD Rehabilitation Toolkit A Guide for Healthcare Professionals Healthy Steps for Peripheral Artery Disease (PAD) Developed by AACVPR and the Vascular.
Ankle Brachial Index Measurement: What is it and why measure it? Mary O’Connor Cardiovascular Medical Science Liason Bristol Myers Squibb Guinness Storehouse.
Clinical Trial Results. org Tilman B. Drüeke, M.D.; Francesco Locatelli, M.D.; Naomi Clyne, M.D.; Kai-Uwe Eckardt, M.D.; Iain C. Macdougall, M.D.; Dimitrios.
Comparison of the New Mayo Clinic Risk Scores and Clinical SYNTAX Score in Predicting Adverse Cardiovascular Outcomes following Percutaneous Coronary Intervention.
R Dhangana, TP Murphy, MJ Pencina, MB Ristuccia, JV Cerezo, D Tsai Prevalence of Low Ankle-Brachial Index, Elevated Plasma Fibrinogen and CRP Among Those.
PAD A Call to Action. PAD: A Call to Action - What is peripheral arterial disease (PAD)? and why is it so dangerous? - Diagnosing PAD in the primary care.
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Uncontrolled Hypertension, Systolic and Diastolic Blood Pressure and Development of Symptomatic Peripheral Arterial Disease in the Women’s Health Study.
Long-term predictive value of assessment of coronary atherosclerosis by contrast- enhanced coronary computed tomography angiography: meta- analysis and.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Management of Dyslipidemia in Patients with Peripheral Arterial Disease: an update from Guidelines Oman International Vascular Conference Al-Bustan Palace.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
Identifying the Presence of Peripheral Artery Disease in Patients With and Without Diabetes Lori Brown, PharmD and Charles Herring, PharmD, BCPS, CPP University.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
Peripheral Artery Disease (PAD) & Ankle Brachial Index (ABI) Marge Lovell RN CCRC CVN BEd MEd London Health Sciences Centre London, Ontario, Canada.
VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.
PAD Diagnosis and Management Gerry Stansby Newcastle upon Tyne, UK.
PAD AND VASCULAR EVENTS  IC AS A DISEASE OFTEN REMAINS UN RECOGNISED. AS HIGH AS 75% OF PEOPLE WHO HAVE IC DO NOT SEEK MEDICAL HELP SINCE MANY PEOPLE.
PAD Guidelines Changes 2005 >>> 2011 Slides by Omron Healthcare Published online September 29, 2011
Cardiovascular Ischemic Event Rates in Outpatients With Symptomatic Atherothrombosis or Risk Factors in the United States: Insights From the REACH Registry.
10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.
PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.
Clinical Trial Results. org Long-Term Prognosis Associated with Coronary Calcification Matthew J. Budoff, MD, Leslee J. Shaw, PhD, Sandy T. Liu, Steven.
Peripheral Arterial Disease in Saudi Arabia : Where Do We Stand? Mohammed Al-Omran, MD, MSc, FRCSC Associate Professor & Vascular Surgeon, King Saud University.
Primordial, primary, secondary, and tertiary prevention stages for global vascular risk. R. Sacco: Stroke, Volume 38(6).June
Can pharmacists improve outcomes in hypertensive patients? Sookaneknun P (1), Richards RME (2), Sanguansermsri J(1), Teerasut C (3) : (1)Faculty of Pharmacy,
1 INTIMA MEDIA THICKNESS AND ATHEROSCLEROSIS Michele CAZAUBON, MD, PhD American Hospital of Paris ( France)
Critical Appraisal Did the study address a clearly focused question? Did the study address a clearly focused question? Was the assignment of patients.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
Ethnic Differences in the Prognostic Value of Coronary Artery Calcification for All-Cause Mortality Khurram Nasir MD MPH, Leslee J. Shaw PhD, Sandy T.
1 “Diabetic foot” Sensory Autonomic Motor. 2 Neuropathic: 45-60% Purely ischaemic: 10% Mixed neuroischaemic: 25-40% Diabetic foot ulceration.
* Based on post hoc analysis of individual outcome events (N=19,185). 1 Data on file, Sanofi Pharmaceuticals, Inc. 2 Gent M. Circulation. 1997; 96 (suppl):
Predictive Value of Coronary Calcium Scoring Matthew Budoff, MD, FACC, FAHA Associate Professor of Medicine UCLA School of Medicine Director, Cardiac CT.
Atherosclerotic Disease of the Carotid Artery Atherosclerosis is a degenerative disease of the arteries resulting in plaques consisting of necrotic cells,
ACC/AHA 2006 guidelines on the management of PAD.
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
Section III. Assessment of Overall Cardiovascular Risk in Hypertensive Patients 2015 Canadian Hypertension Education Program Recommendations.
Exercise Management Peripheral Arterial Disease Chapter 15.
Baseline characteristics. Patient flow Completed Completed Perindopril Placebo Randomised Not randomised Registered.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
A Review of – Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Ted Williams Pharm D Candidate Monday Lab.
Medical Management of Claudication: Just Walk it Off!!
Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
Peripheral Artery Disease in Orthopaedic Patients with Asymptomatic Popliteal Artery Calcification on Plain X-ray Adam Podet, MS; Julia Volaufova, phD,;
Incidence of Abnormal Ankle-Brachial Index in Diabetic Patients Asymptomatic of Arteriosclerotic Vascular disease Brintha Vasagar, MD, MPH, Katee Castleman,
Women reaching equality in health, despite the differences Nowadays women remain the largest CAD population subgroup being under-diagnosed and under-treated.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Left Ventricular Filling Pressure by Doppler Echocardiography in Patients With End-Stage Renal Disease Angela Y-M Wang, Mei Wang, Christopher W-K Lam,
CoRPS Center of Research on Psychology in Somatic diseases Brief Depression Screening with the PHQ-2 Predicts Poor Prognosis following PCI with Drug-Eluting.
PAD DR. SHWETA PHADKE..
Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:
Clinical need for determination of vulnerable plaques
LDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial Marc P. Bonaca, Patrice.
PS Sever, PM Rothwell, SC Howard, JE Dobson, B Dahlöf,
AIM HIGH Niacin plus Statin to prevent vascular events
First time a CETP inhibitor shows reduction of serious CV events
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
FATS- Familial Atherosclerosis Treatment Study
Jane Armitage on behalf of the HPS2-THRIVE Collaborative Group
Baseline characteristics of HPS participants by prior diabetes
Correlation between endothelial function and hypertension
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Presentation transcript:

C. Diehm, 2007 Excess cardiovascular mortality in patients with peripheral arterial disease in primary care: 5-year results of the getABI Study Diehm C, Trampisch HJ, Holland-Letz T, Allenberg JR, Haberl R, Mahn M, Tepohl G, Pittrow D, Darius H Acknowledgement getABI is supported by an Unrestriced Eductional Grant by Sanofi-Aventis, Berlin (since 2001) and by the German Ministry of Health (from 2008 onwards)

C. Diehm, 2007 Conflict of interest For the getABI Study we got an unrestricted grant by Sanofi - Aventis. This study includes no marketing strategies. Apart of this I have no potential conflict of interest to report.

C. Diehm, 2007 Background: rationale  Peripheral arterial disease (PAD) - outdated view: important as local vascular event (amputation) - current view: indicator disease for generalised atherothrombosis predicts myocardial infarction and stroke  Key questions - Frequency of asymptomatic and symptomatic PAD in primary care - Feasibility of the Ankle Brachial Index - for PAD diagnosis - for cardiovascular risk stratification  Epidemiological studies in primary care needed

C. Diehm, 2007 Background: Ankle Brachial Index ABI: highly specific for leg artery stenosis > 50%, highly sensitive (95 %), takes 10 minutes, recommended in important guidelines (AHA/ACC 1, TASC II 2 etc.) 1 Hirsch AT Circulation 2006;113: Norgren et al. Eur J Vasc Endovasc Surg 2007;33(Suppl. 1):S1-S75. To date, the ABI is the most effective, accurate and practical method of PAD detection (quick, easy, non invasive, cost effective) Systolic blood pressure at ankle should be at least as high as pressure in the arm, i.e. ankle brachial index > 1.0 If ankle pressure is lower than brachial pressure, stenosis is likely i.e. ankle brachial index < 0.9 = PAD Severe moderate mild boderline healthy __________PAD_____________________ 1.0

C. Diehm, 2007 Study aims  Prevalence and incidence of PAD  to quantify the risk of death and severe vascular events of patients with (asymptomatic or symptomatic) PAD vs. those without PAD  to investigate the risk increase according to different ABI categories including the 0.9–1.1 category, which is conventionally regarded as ‘no disease’,  to assess the contributions of known risk factors including PAD to the overall risk of death and severe events.

C. Diehm, 2007 Methods  Patients: 6,880 unselected patients ≥ 65 years in 344 representative German practices  Visits: at baseline and 6, 12, 36, 60 months (study ongoing).  Severe vascular events: death, myocardial infarction (MI), coronary/carotid/ peripheral revascularisation, stroke, amputation due to PAD. All events reported by GPs. Cardio-/cerebrovascular deaths were verified by hospital data or GP records.  Asymptomatic PAD: ABI <0.9 determined with standard Doppler sonography (excluding claudication), using the higher of the two systolic pressures in the leg (posterior tibial or anterior tibial) was used. ABI training and supervision of GPs by vascular experts.  Symptomatic PAD: comprised intermittent claudication, or PAD - related amputation or revascularisation.

C. Diehm, 2007 Background characteristics (baseline) 20.8

C. Diehm, 2007 Atherothrombotic co-manifestations cerebral PAD coronary Angina pectoris, MI, coronary revasc. TIA, stroke, Carotid revascularisation 63.5 % any 12.2 % 4.4 % 11.2 % 1.8 % 1.1 % 4.1 % 1.6 % Diehm et al. Atherosclerosis 2004;172:

C. Diehm, 2007 Prevalence of PAD* ** (ABI < 0.9) Prevalence of PAD* ** (ABI < 0.9) women:16.8 % (34.8) men:19.8 % (34.0) total:18.0 % (35.5) women:16.8 % (34.8) men:19.8 % (34.0) total:18.0 % (35.5) * Distal calf occlusions/stenoses not included (left) ** Distal calf occlusions/stenoses included ( ) * Distal calf occlusions/stenoses not included (left) ** Distal calf occlusions/stenoses included ( )

C. Diehm, 2007 Mortality (all-cause), by PAD category, at 5 yrs

C. Diehm, 2007 Mortality (all-cause, by PAD status) at 5 yrs

C. Diehm, 2007 Survival (all-cause, by PAD status) at 5 yrs

C. Diehm, 2007 Mortality (all-cause, by ABI category) at 5 years

C. Diehm, 2007 Association between PAD (and other known vascular risk factors) and death of any cause CI = confidence interval; PAD = peripheral arterial disease (symptomatic: history of peripheral revascularization or amputation or claudicatio intermittens, asymptomatic: ABI < 0.9 and no symptomatic PAD at baseline); a = myocardial infarction, cardiac revascularization, stroke, revascularization at carotids With the exception of hypertension and hyperlipidemia, a significant association was observed between all cardiovascular risk factors investigatet

C. Diehm, 2007 PAD patients are undertreated 0%10%20%30%40%50%60%70%80%90%100% Only CVD / CHD (Stroke, MI Or coronary revascularisation) PAD only betablockers statins Platelet inhibiting drugs * * ASS, Ticlopidin Or Clopidogrel p < 0.001

C. Diehm, 2007 Conclusions  PAD is common in primary care  PAD patients have a substantially increased risk of death  Asymptomatic and symptomatic PAD do not significantly differ in terms of risk  PAD is a strong and independent risk predictor compared to conventional risk factors  ABI category counts!  Detecting PAD is important to aid in the management of these patients to reduce the risk of cardiovascular events.

C. Diehm, 2007 Conclusions (ABI)  ABI is feasible in primary care  The ABI is sensitive, specific and reliable for the detection of PAD  The ABI is a good predictor of risk for future cardiovascular events and mortality  These data support existing guidelines that PAD should be routinely employed in primary care

C. Diehm, 2007 CALL TO ACTION  Implement ABI as screening tool in general practice to identify high - risk patients PAD is too important to leave it to specialists alone…  Screen elderly patients (and those with additional risk factors) systematically for PAD  Initiate treatment in PAD along the standards of coronary artery disease  PAD patients are no longer second - class atherothrombotic patients

C. Diehm, 2007 Possible slides for discussion

C. Diehm, 2007 How to messure ABI Systolic blood pressure in the brachial artery is measured in both arms using a Doppler detector in the antecubital fossa The blood pressure cuff is then applied to the ankle, and the Doppler used to determine systolic pressure at the left and right posterior tibial arteries and dorsalis pedis arteries. The ABI for each leg is the ratio of the higher of the 2 systolic pressures (posterior tibial or dorsalis pedis) in the leg and the average of the right and left brachial artery pressures, unless there is a discrepancy > 10 mmHg in blood pressure values between the 2 arms. In such cases, the higher reading is used for the ABI. Recent data have indicated that use of the lower 2 ankle systolic pressures may improve the diagnostic yield. Pressures in each leg should also be measured and ABI calculated separately for each leg. An ABI < 0.90 in either leg is generally considered indicative of PAD, and progressively lower ABI values indicate more severe disease.

C. Diehm, 2007 Only 1 in 10 of these PAD patients will have classical symptoms of intermittent claudication 1 in 5 elderly people (aged ≥65 years) visiting the GP has PAD (defined as ABI <0.9) If one relies solely on classical symptoms of intermittent claudication you will not ‘see’ much PAD PAD is usually asymptomatic Diehm C et al. Atherosclerosis 2004; 172(1): 95–105

C. Diehm, 2007 Undertreatment of PAD patients